PR95184

SHANGHAI, March 28, 2022 /PRNewswire=KYODO JBN/ --

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec(TM))

recently announced that it has received registration approval from Japan

Pharmaceuticals and Medical Devices Agency (PMDA) for its

independently-developed Hyperflex(R) Balloon Catheter (Hyperflex(R)) as the

company's first product approved for marketing in Japan. Hyperflex(R) obtained

CE Mark in 2016 and is already available in overseas markets in South America

and Asia.

Hyperflex(R) is intended to assist in the dilation of aortic stent graft. It

uses a compliant TPU balloon to expand the deployed stent graft, which enables

improved adherence to the vascular wall, minimizes type I/III endoleaks, and

improves stent positioning for better short- and long-term outcomes. When used

in conjunction with the aortic stent graft system, Hyperflex(R) provides an

integrated endovascular aneurysm repair(EVAR) solution, making it easier and

more flexible.

Mr. Qing Zhu, President of Endovastec(TM), stated, "The approval of the

Hyperflex(R) Balloon Catheter in Japan signals a growing acceptance of our EVAR

devices in more and more national and regional healthcare systems, paving the

way for the company's continued marketing in Asia and the globe. Endovastec(TM)

will continue to innovate to improve solutions for aortic diseases and reach

more patients worldwide with better products and services."

About Endovastec(TM)

Founded in Shanghai in 2012, Shanghai MicroPort Endovascular MedTech (Group)

Co., Ltd. ("Endovastec(TM)", Stock code: 688016.SH), a subsidiary of MicroPort

Scientific Corporation ("MicroPort(R)", Stock code: 00853.HK), is a global

medical devices company focusing on R&D, manufacturing, and sales of aortic and

peripheral vascular interventional devices, with main products of thoracic and

abdominal aortic stent grafts, stent grafts in surgical operation, drug coated

PTA balloon catheters, and PTA balloon catheters etc. At Endovastec(TM), we are

breaking barriers and accelerating access to provide trustworthy and universal

access to state-of-the-art solutions of prolonging and reshaping all lives, and

to build a people centric enterprise ranking as a global leader of evolving and

emerging medical technologies through continuous innovation.

SOURCE: Endovastec